ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1700

Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions

Mikhail Olferiev1, Kyriakos Kirou1, Emily Wu2, Dina Greenman1 and Mary Crow3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Union City, NJ, 3Hospital for Special Surgery, New York

Meeting: ACR Convergence 2025

Keywords: Epigenetics, Gene Expression, genomics, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Genetics, Genomics & Proteomics (1698–1703)

Session Type: Abstract Session

Session Time: 3:30PM-3:45PM

Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the female predominance of SLE, recent interest has focused on the immune functions conferred by the two X chromosomes in women. To identify unique mechanisms that may result in SLE in males, we generated RNA transcript data from male and female subjects with SLE or from healthy individuals.

Methods: Female and male SLE patients were characterized in detail based on demographic, clinical and laboratory features. Multiple correspondence analysis of 95 parameters was used to optimally match 15 female and 15 male SLE patients, along with healthy donors. A PBMC sample for RNAseq analysis was selected for each patient at the time of their lowest level of disease activity. RNA sequencing was performed and data analyzed using principal component analysis (PCA) and determination of differentially expressed gene transcripts.

Results: PCA distribution of RNAseq data showed male SLE patients distinct from healthy males and female SLE patients. As observed for the overall SLE population, type I interferon-stimulated genes dominate transcripts differentially expressed between SLE males and healthy males, with SLE males also showing higher expression of NFkB pathway genes and pro-inflammatory cytokines/chemokines compared with healthy males. Among the differentially expressed genes, 4 Y chromosome-encoded transcripts (TXLNGY, ENSG00000267793, BCORP1 and KDM5D) were significantly decreased in SLE males compared with healthy males and 1 Y chromosome-encoded gene (EIF1AY) was increased in SLE males. Of those, KDM5D, also called SMCY, encoding lysine demethylase 5D, is of particular interest as it mediates the removal of methyl groups from histone lysine residues at the K4 position and regulates both promoters and enhancers throughout the genome. Remarkably, review of the Y chromosome location of those differentially expressed genes revealed that all 5 genes share a portion of a genomic locus (termed AZFb) in the male-specific region of Y that is associated with microdeletions and male infertility.

Conclusion: Males with SLE demonstrate altered expression of several genes occupying a common Y chromosome locus, along with increased expression of NFkB and pro-inflammatory cytokine genes. Among the Y chromosome-encoded transcripts decreased in male SLE, KDM5D, a histone demethylase, warrants further investigation. KDM5D is expressed in multiple cell types and may contribute to impaired epigenetic regulation and activation of inflammation-related pathways throughout the genome. Our data suggest that males with SLE may be enriched in genomic Y chromosome variants that contribute to altered immune function.


Disclosures: M. Olferiev: None; K. Kirou: AMPEL Biosolutions, 5, Bristol-Myers Squibb(BMS), 5, Novartis, 5; E. Wu: None; D. Greenman: None; M. Crow: Abelzeta, 1, Aboleris, 1, AMPEL Biosolutions, 1, AstraZeneca, 1, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, Gilead, 5, GlaxoSmithKlein(GSK), 1, Novartis, 1, Palleon, 1.

To cite this abstract in AMA style:

Olferiev M, Kirou K, Wu E, Greenman D, Crow M. Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/altered-gene-expression-in-male-sle-is-mapped-to-a-male-specific-y-chromosome-locus-associated-with-microdeletions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-gene-expression-in-male-sle-is-mapped-to-a-male-specific-y-chromosome-locus-associated-with-microdeletions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology